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3.1. Small RNAs 
3.1.1. The history of RNAi and miRNA – a summary 
In 1958, Crick presented the idea of the central dogma of molecular biology, which states that 
the information from DNA is passed in a one-way direction via RNA to proteins [1]. Since 
then, one of the most important questions in molecular biology has been how the expression 
of proteins is regulated. The first time RNA was proposed as a regulator of protein expression 
was in 1969, when Britten and Davidson proposed a theory in which RNA might regulate the 
expression of genes using standard Watson-Crick base-pairing rules [2]. However, the idea 
that RNA could govern the expression profile of each cell type was neglected when 
transcription factors were discovered, and for decades transcription factors (there is an 
estimate of ~1500 transcription factors in the human genome [3]) were seen as almost 
exclusive effectors for regulating the mRNA expression profile and the proteome of 
eukaryotic cells.  
It was not until the early 1990s that hints of expressional regulation of one mRNA caused by 
another RNA started to emerge. In 1990, it was reported that the overexpression of exogenous 
DNA encoding an enzyme, producing a purple pigment in petunias, led to white flowers as a 
consequence of a reduced expression of both endogenously and exogenously introduced 
enzyme mRNA [4, 5]. The downregulation of mRNA levels by the introduction of antisense 
RNA was an established technique as early as 1984 [6], but it was shown in 1995 that both 
antisense and surprisingly the synthetically produced sense RNA induced the silencing of 
gene expression in Caenorhabditis elegans [7]. In 1998, Fire and Mello demonstrated that this 
silencing was triggered by dsRNA and that the sequence of the dsRNA determined which 
mRNA was targeted for silencing [8]. Three years later, the same method  was also shown to 
be a functional tool in mammalian cells [9] and that the concept of RNA-based gene silencing 
is functional in all eukaryotic supergroups (with a few exceptions, including budding yeast, 
which seems to have lost this feature during evolution) [reviewed in 10]. This mechanism is 
called RNA interference (RNAi) 
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At the same time as the mechanism of RNAi was discovered, another small RNA started to 
make its appearance. In 1993, Ambros et al. described lin-4 as the first micro RNA (miRNA) 
in the nematode C. elegans. Here, it was shown how the smaller RNA lin-4 seemed to repress 
the translation of the larger mRNA lin-14 and that this repression might be a result of multiple 
RNA-RNA interactions between lin-4 and the 3’ UTR structure of lin-14 [11]. In 2001, 
miRNA was established as a large class of gene regulators in several species including 
humans [12-14], thereby suggesting that miRNA and the proteins involved in its regulation 
are a part of a conserved pathway.  
In 2001, RNAi and miRNA were linked together when it was demonstrated that Dicer, a 
protein that sliced long dsRNAs into smaller effector RNAs called small interfering RNAs 
(siRNAs) [15, 16], also converted longer lin-4 transcripts into smaller mature lin-4 miRNAs 
[17-19]. As a result, it was now apparent that both RNAi and miRNA were regulatory tools 
conserved in most eukaryotes and that they both used the same pathway to exert their 
regulatory effect on mRNAs.  
3.1.2. The miRNA pathway in animals 
There are two main differences between miRNA and siRNA in animals: 
1. MiRNAs are transcribed endogenously from non-protein-coding separate genes. There 
are no dedicated genes for siRNAs. Instead, they are degraded from larger dsRNA 
introduced to the nucleus exogenously (e.g. viral transcripts) or endogenously (e.g. 
transposons) [20]. 
2. SiRNAs have a full complementarity towards their targets, while miRNA show a 
limited complementarity.   
The main features of the miRNA pathway are outlined in Figure 1.  
MiRNA genes are primarily transcribed by RNA polymerase II to form primary miRNA (pri-
miRNA), a structure which is usually several kilobases long, with local stem loop structures 
[21, 22]. They can be encoded in independent transcription units, in polycistronic clusters or 
within introns of protein coding or non-coding genes [reviewed in 23]. The pri-miRNA is 
further processed in the nucleus into a hairpin approximately 60-70 nucleotides long, which is 
known as the precursor miRNA (pre-miRNA) [24]. This processing is done by the 
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Ribonuclease III (RNase III) protein Drosha and its essential co-factor DiGerorge syndrome 
critical region 8 (DGCR8) [25-29]. After processing, the pre-miRNA hairpin contains a 3’ 2 
nt overhang and a 5’ mono-phosphate group [25, 30, 31], a feature that is characteristic of all 
RNAs cleaved by an RNase III protein [32]. Polycistronic clusters are transcribed as a single 
transcript, which is processed into all the separate miRNAs within the cluster by Drosha [12, 
13]. 
Pre-miRNA exits the nucleus through nuclear pore complexes since further processing of the 
pre-miRNA takes place in the cytosol. This transport is executed by the nuclear transport 
receptor exportin-5 (exp5), which recognises dsRNA hairpins with stems >16bp long [33-35]. 
The 3’ overhang of 2 nt further facilitates this process [36].  
Following release into the cytoplasm, the pre-miRNA is recognised by and bound to the 
RNase III enzyme Dicer, which cuts it to generate a mature miRNA [16-19]. Dicer contains 
both an RNase III domain (RIIID) responsible for slicing dsRNA and a highly conserved Piwi 
Argonaute Zwille (PAZ) domain which recognises and binds the 3’ dinucleotide overhang on 
the 3’ end of the pre-miRNAs [15, 37]. This suggests that the 3’ dinucleotide overhang locks 
into the PAZ-domain, bringing the pre-miRNA into position for cleavage by the RIIID of 
Dicer [38]. Human Dicer then cuts the pre-miRNA stem approximately 22 nt from the 3’ end 
docked in the PAZ domain [39]. A crystal structure of Dicer from the parasite Giardia reveals 
that the distance from the PAZ-domain to the RIIID matches the length of the Giardia Dicer 
cleavage products [40], thus suggesting that Dicer itself acts as a molecular ruler which 
generates products defined in length by the fixed distance between its PAZ domain and RIIID. 
The pre-miRNA is now reduced to an approximately 22 nt dsRNA, with a 3’ dinucleotide 
overhang and a 5’ phosphate group at both ends. 
Dicer works together with several other proteins in order to execute its function. Dicer 
containing the sliced dsRNA is recruited by the trans-activation-response RNA-binding 
protein (TRBP) to form a structure known as the RNA-induced silencing complex (RISC) 
loading complex [41, 42]. Here, the mature miRNA is transferred from Dicer to the RISC 
where it binds to an Argonaute (Ago) protein, which is the catalytic entity of the RISC [43, 
44]. Of the two Ago proteins encoded in humans, Ago2 is functioning in the RNAi pathway 
[43, 44]. Ago2 also contain a PAZ domain, which recognises the presence of a 3’ dinucleotide 
overhang and a 5’ phosphate group on dsRNA, both of which are facilitating the incorporation 
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of the miRNA to the RISC [45-47]. After the transfer of the RNA duplex, it is the strand with 
its 5’ end at the least thermodynamically stable end that is preferentially kept bound to Ago2 
[48]. This strand is known as the guide strand, while the complementary passenger strand is 
cleaved and degraded [49]. When bound to the RISC, the guide strand functions as a 
sequence-specific template that leads the RISC to complementary targets through base-pairing 
interactions.  
MiRNAs does not usually have a full complementarity with its targets. When bound to RISC, 
only nucleotides numbered 2-6 of the guide strand (starting from the 5’ end) are exposed to 
such a degree that base-pairing with target RNA is possible [50]. This is in accordance with 
the observation that animal miRNAs contains a seed region ranging from nt 2-8, which is 
critical for the specificity of target recognition [51-53]. MiRNAs usually exert their regulatory 
functions by binding to a complementary seed sequence in the 3’UTR of their target mRNA, 
although binding to the 5’UTR or the coding regions has also been reported [54]. When the 
targeted mRNA is bound to the RISC, it can be moved from the cytosol to cytoplasmic 
complexes called Processing bodies (P-bodies) [55-57]. Here, de-adenylation and de-capping 
of the mRNAs followed by 5’→3’ degradation occurs [56, 58]. In addition, the protein 
translation of the mRNAs is prevented as they become sequestered from the ribosomes 
residing in the cytosol. Nevertheless, degradation of mRNA accounts for the vast majority of 
miRNA induced gene silencing [59]. 
If there is perfect complementarity between the bound guide strand and its target, the target is 
not transported to P-bodies. Instead, Ago2 cuts the target RNA between the 10th and 11th 
nucleotide as measured from the 5’ end of the guide strand [46, 47, 60-62]. 
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Figure 1: The miRNA pathway. MiRNA genes are transcribed to pri-miRNA often several kilobases long 
(1). Pri-miRNA is then processed by Drosha to form hairpin structures known as pre-miRNA (2). 
Exportin 5 recognizes the hairpin structure by its 3’ dinucleotide overhang, and exports it from the 
nucleus to the cytoplasm (3). In the cytoplasm, pre-miRNA is recognized by Dicer, which cuts the pre-
miRNA into a mature miRNA ~22 nt long (4). The dsRNA is then transferred into the RISC, where the 
passenger strand is cleaved and removed. The guide strand is used as a template for binding target mRNA 
according to base-pairing. If there is full complementarity, the mRNA is cleaved. If there is partial 
complementarity, the mRNA is transferred to P-bodies where translation is repressed and the mRNA is 
eventually degraded (5), see text for details. Modified by permission from Macmillan Publishers Ltd: 
Gonzalez-Alegre, P. and H.L. Paulson July, 2007. "Technology insight: therapeutic RNA interference--
how far from the neurology clinic?" Nat. Clin. Pract. Neurol. 3(7):394-404. 
8 
3.1.3. The natural functions of RNAi in animals 
Since Argonaute-like and Dicer-like proteins are present in all eukaryotic supergroups, it is 
evident that dsRNA-mediated silencing was already established in the last common ancestor 
of eukaryotes, but that it was also not required for life since it has been lost several times in 
various single-cellular organisms [reviewed in 10]. DsRNA-based silencing has probably 
evolved as a defence mechanism against genomic parasites such as tranposons and viruses 
[63-68]. Until recently, it has been assumed that defence is the main task of RNAi systems in 
mammals. Still, the discovery of endogenous siRNA (endo-siRNA) transcribed from L1 
transposons in human cultured cells has opened the possibility of additional tasks for siRNA 
[69]. It has been shown in mouse oocytes that transcribed pseudogenes interact with 
homologous protein coding mRNAs to form dsRNA being processed to 21 nt siRNAs by 
Dicer [70, 71]. 
  
3.1.4. The natural functions of miRNA in animals 
Thus far, miRNAs have only been described in multi-cellular organisms, in which they have 
evolved to regulators essential for the development of both animals and plants [23, 72-74]. 
Exactly when miRNAs evolved in evolution is debated, although it seems that the regulation 
of genes by miRNAs could be a requirement for the emergence of multi-cellular organisms 
since both plants and animals have evolved miRNA systems out of a separate evolutionary 
origin [10, 75]. From its discovery, it has taken miRNA merely a decade to achieve status as a 
regulator of most biological processes in animals and plants, including cell cycle, 
differentiation, development and metabolism [13, 76-78]. The number of mature miRNA 
products in the human genome has exceeded 1000 (mirBase version 16.0), while it is 
estimated that more than 60% of human mRNAs contain conserved miRNA target sites in 
their 3’ UTR [79]. This means that on average each miRNA can target a large amount of 
mRNAs, e.g. the miR-15a/16-1 cluster, which is predicted to potentially control 14% of all 
genes in the human genome [80]. To further add to this complexity, in most cases mRNAs 
harbour target sites for several different miRNAs [81-83]. Given the immense complexity and 
biological importance of miRNAs, it is of no surprise that their dysregulation is implicated in 
a vast number of human diseases, e.g. cancer, diabetes, muscular disorders and even 
psychiatric diseases [84-87]. MiRNAs were shown to potentially act as both oncogenes and 
9 
tumour suppressors in 2005 [88-91], and the dysregulation of miRNAs is now regarded as a 
vital contributor to the pathogenesis of many tumours [92, 93]. 
3.1.5. Targeted gene regulation using exogenous RNA 
Previously, antisense technology was the most feasible approach for reducing the expression 
of specific genes, and both antisense DNA and RNA have been used for the modulation of 
biological processes [reviewed in 94]. However, since the discovery of RNAi, these 
approaches have been superseded, given the higher efficiency of RNAi compared to antisense 
technologies [95-97]. Scientists can now exploit RNAi to suppress virtually any gene simply 
by introducing siRNAs that are perfectly complementary to the target of interest. The miRNA 
biogenesis pathway contains three distinct RNA intermediates: the pri-miRNA transcript, the 
pre-miRNA hairpin and the miRNA duplex. All of these intermediates can be exploited as 
entry points for RNAi (Figure 2). 
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Figure 2: The process of RNAi and its manipulation. For a description of the miRNA pathway, confer 
with Figure 1. RNAi can be initiated by introducing siRNA or shRNA stems at all steps in the miRNA 
pathway, see text for details (Chapter 3.1.5). Modified by permission from Macmillan Publishers Ltd: 
Gonzalez-Alegre, P. and H.L.Paulson July 2007. "Technology insight: therapeutic RNA interference--how 
far from the neurology clinic?" Nat. Clin. Pract. Neurol. 3(7):394-404. 
Imitating the miRNA duplex: siRNA 
Synthetic siRNAs are small RNA duplexes designed to imitate the mature miRNA duplex in 
order to obtain RNAi-mediated gene suppression. In the first study, in which RNAi were 
shown to mediate effective silencing, dsRNA fragments several hundred nucleotides long 
were used [8]. Even so, the presence of long dsRNA in the cytoplasm often triggers the non-
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specific interferon response pathway in mammalian cells, thereby leading to a broad 
inhibition of protein synthesis, transcriptional activation of cytokines and ultimately cell death 
[reviewed in 98]. It is generally believed that dsRNA molecules less than 30 bp long are not 
able to induce the interferon response [99]. Nonetheless, this is debated, and it has been 
demonstrated that the triggering of the interferon response pathway by dsRNAs >23 nt long is 
cell-type dependent [100]. To prevent activation of the interferon pathway, researchers have 
generally used shorter siRNAs (19-23 bp) that imitate the products of Dicer [46]. To further 
mimic natural Dicer products, siRNAs are also designed with a dinucleotide 3’ overhang in 
both ends for more efficient loading [47]. It is the strand with the least thermodynamically 
stable 5’ end which is preferred as the guide strand [48]. To ensure that the desired strand is 
loaded onto RISC, siRNAs are constructed with accordingly GC bp asymmetry.   
Imitating the pre-miRNA: Synthetic Dicer products and shRNA 
Synthetic Dicer products are 25-30 bp RNA duplexes designed to interact directly with Dicer 
[101]. They contain only one 3’ dinucleotide overhang to ensure that Dicer cuts the RNA at 
the intended end, thereby producing identical mature siRNAs with the predicted sequence 
[102]. As a result, synthetic Dicer products mimic cytoplasmic pre-miRNA. 
While siRNAs and Dicer products are introduced as RNA directly to the cytoplasm, short 
hairpin RNAs (shRNAs) are transcribed from DNA in the nucleus of the cell before they are 
exported by exp5 to the cytoplasm for further processing by Dicer and loading into the RISC 
[103]. ShRNAs are generally transcribed from RNA polIII into hairpins, thus mimicking 
nuclear pre-miRNA. In the appendix, we show that cloning of vectors expressing shRNAs are 
an easy and inexpensive technique for achieving efficient knockdown of a desired target gene. 
The RNA polIII promoter is located directly upstream of the gene it is transcribing. It has a 
well defined starting point, and terminates when transcribing 4-5 consecutive thymidines 
[reviewed in 104]. When transcribed in the nucleus, the shRNAs folds into hairpins with a 3’ 
dinucleotide overhang in one end and a loop in the other. The stem of the hairpin usually 
ranges from 23 to 29 bp. This configuration is similar to pre-miRNA constructs, and is 
therefore recognised as substrates by exp5 and Dicer [105-110]. Regardless of the initial 
length of the hairpin, Dicer cuts the shRNA into ~22 nt effector dsRNAs before incorporation 
to the RISC [39].  
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Imitating the pri-miRNA: shRNA-mir 
RNA transcribed from PolII promoters includes elements such as 5’ end caps and 3’ polyA 
tails. These elements must be removed by Drosha before the transcript can interact with exp5 
and the remaining miRNA pathway [22]. For this reason, polII promoters were initially 
avoided for transcription of shRNAs. However, shRNAs can also be expressed from RNA 
PolII promoters by inserting the hairpin within the backbone of a miRNA (usually that of 
miR-30), resulting in a primary transcript with extensive length and folding compared to 
standard shRNAs [111, 112]. Consequently, this shRNA-mir transcript is a target for 
processing by Drosha, and utilises the full miRNA pathway instead of accessing it in 
downstream entry points. 
3.1.6. Efficiency of RNAi 
All of the above described forms of RNAi exploit the miRNA pathway to exert their effect, 
and they can all be transiently transfected for short-term suppression of a desired gene. To 
evaluate the efficiency of the various constructs, one important aspect to consider is how 
much mRNA the construct is able to suppress on a numerical basis.  
SiRNAs enter the miRNA pathway directly into the RISC, which means that they are not 
bound or processed by Dicer. The main function of Dicer is to cleave long dsRNAs into 
shorter products, but it is also a vital part of the RISC loading complex, which strongly 
facilitates the transfer of the guide strand into the RISC. Since siRNAs <23 bp are loaded 
directly onto the RISC, they are not able to take advantage of this feature [101, 113]. Dicer 
products are designed to interact with Dicer, and have been shown to be more efficient than 
siRNAs targeting the same target sequence [39, 101, 114]. 
There are three promoters used to express shRNAs: the H1, U6 and tRNA promoter [115]. Of 
these, the U6 and H1 promoters are generally being favoured, and it has been debated as to 
which of these promoters is the most efficient. Some groups find that U6 is the most effective 
in terms of expressed shRNA and the duration of gene suppression [115, 116], while others 
groups find no significant difference [117]. Our results reveal that the efficiency may vary 
between cell-lines but that the U6 promoter usually demonstrated a marginally higher 
efficiency (Paper I, [118]). This suggests discrepancies depending on different variables such 
as type of target cells, delivery method and shRNA sequence and that the most efficient 
13 
promoter should be decided on a case-by-case basis. Since shRNAs are processed by Dicer, 
they are also inserted into the RISC with higher efficiency than siRNAs. It has been shown 
that shRNAs expressed from a U6 promoter are more than 100 fold more effective on a 
numerical basis than siRNAs containing the same target sequence [115]. Nonetheless, a 
vector containing the shRNA is often 100 fold larger than naked siRNA. In addition, the 
vector needs to enter the nucleus in order to be transcribed, which is shown to be one of the 
biggest challenges when transfecting [119]. For that reason, the number of shRNA transcripts 
actually being produced is much lower than the number of siRNAs being introduced to the 
cytoplasm when the same amount of nucleic acid by weight is transfected. As a result of this, 
the practical gene suppression efficiency ranges from similar to slightly better for siRNAs 
compared to shRNAs [105, 115, 120]. 
By expressing the shRNA placed within the backbone of a miRNA, the resulting shRNA-mir 
is processed by Drosha in the same manner as the miRNA itself. MiRNAs are almost 
exclusively expressed from RNA polII promoters, as opposed to traditional shRNAs which 
are generally expressed from polIII promoters. The suppression efficiency of identical 
shRNAs expressed from either PolII or PolIII promoters has been compared with conflicting 
results. It has been shown that shRNA-mir expressed from a CMV PolII promoter slightly 
outperformed the shRNA transcribed from a U6 RNA polIII promoter [121]. Boden et al. 
reported that the transient expression of shRNAs from PolII promoters with miRNA 
backbones significantly outperformed conventional shRNAs [122], while it has also been 
reported that conventional shRNAs are more efficient than shRNA-mir [123]. Boudreau et al. 
however have stated that the above reports could be flawed as a result of missing 3’ 
dinucleotide overhangs in addition to the failure to consider the effect of GC asymmetry in the 
stem when the conventional shRNAs were designed. When these important features are under 
control, it has been shown that conventional shRNAs are more potent than shRNA-mirs for 
three different target sequences, both in vitro and in vivo [124]. It is not clear whether this is a 
result of increased expression or higher stability of the transcribed shRNA in comparison to 
shRNA-mir. 
3.1.7. Duration of RNAi-based gene suppression 
It is only possible to introduce synthetic siRNAs and Dicer products to cells in a transient 
manner, which means that all gene suppression resulting from these synthetic RNAs is only 
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temporary. Bartlett and Davis found that it seems as if the duration of siRNA-mediated 
knockdown is dependent on how fast the harbouring cells are dividing [125]. Here, it was 
demonstrated that the levels of the targeted genes returned from optimal knockdown at 24-48 
hours to background levels within six days in the dividing cells, and similar dynamics have 
been reported by other groups [114, 126]. However, it has also been reported that the 
maximum amount of introduced siRNA molecules peaks at approximately 24 hrs and 
diminishes within 48 hrs, which indicates a high degradation and turnover [127]. It has been 
shown that transiently transfected vector-based shRNAs give more durable gene suppression 
than the transfection of siRNA since shRNAs can be continuously transcribed by the host cell 
as long as the vector remains in the nucleus [115]. There are two main concerns when 
considering gene suppression using RNAi with transiently transfected effectors. First, all 
transient expressions by definition are temporal, and suffer from dilution effects as a result of 
cell division and RISC turnover. Because of this, it is not possible to maintain gene 
suppression for more than a week (our unpublished results). Second, transfection efficiency is 
rarely 100% and might vary considerably between cell lines. As a result, there will always be 
a background of cells without gene suppression, and this untransfected fraction could vary 
considerably between different cell lines (our results). Vector-based RNAi has the advantage 
of being able to produce stable gene suppression through the insertion of the expression 
cassette into the genome of cells, which is an approach that solves both concerns mentioned 
above. 
3.1.8. Strategies for achieving stable shRNA expression 
When an expression cassette is inserted into the genome of a cell, it will not be lost and will 
be inherited to all offspring. Therefore, the expression of shRNA will remain in the entire cell 
population. Generally speaking, an expression cassette being genomically inserted is coded on 
the same plasmid as a construct expressing an enzyme, making the stably transfected cell 
resistant towards a selection marker. When this selection marker is later added to cell media, 
untransfected cells will die, leaving behind a population in which all cells express the desired 
shRNA. Thus, stable transfection will generate populations in which all cells are transfected, 
and gene suppression does not diminish over time. 
There are several strategies for the stable delivery of exogenous DNA to cells [reviewed in 
128]. The ones most used in RNAi strategies are random plasmid integration [105, 106] and 
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viral delivery [129-131]. In random plasmid integration, cells are transfected by any 
conventional method [reviewed in 128]. On rare occasions, transfected DNA is integrated into 
the genome of the cell in a random manner. These relatively rare cells will then be able to 
produce resistance towards a selective drug on a permanent basis, and therefore can be sorted 
out from the majority of cells not being stably transfected. As a consequence, the expression 
of the inserted transgene may vary between clones. Transgenes inserted in high density 
chromatin areas generally show a low expression, whereas insertion in low density areas 
suggests a higher expression. The plasmid might have been linearised in a manner that 
resulted in expression of only the resistance gene and no functional version of the transgene. 
Additionally, the number of copies being inserted may vary [reviewed in 128], which means 
that every clone should be controlled for plasmid integrity and expression. 
Retroviral vectors have become an important tool for stable gene transfer both in vitro and in 
vivo. Retroviruses are constituted of RNA packed into a capsid and a membranous envelope. 
When the virus infects a cell, it transfers the RNA into the target cell, where it is reverse 
transcribed in the cytoplasm and integrated randomly into the genome [reviewed in 132]. The 
frequently used Moloney murine leukemia virus (MLV) retroviruses are not able to cross the 
nuclear membrane, and are thereby only able to integrate into the genome when the nucleus is 
disassembled during mitosis [133]. For this reason, MLV retroviruses are only able to infect 
dividing cells. Lentiviruses are a complex class of retroviruses which are able to also 
transduce non-dividing cells [reviewed in 134]. Both classes of retroviruses are mainly 
adapted in the same manner for transductions in laboratories. Genes encoding proteins that are 
necessary for the assembly of the envelope are transcribed from a packaging cell line, which 
is transiently transfected with the remainder of the viral genome containing an inserted 
transgene and a resistance gene. This leads to the release of functional viruses which codes for 
the insert, but not for the envelop proteins into the media. The media containing viral particles 
can then be used to transduce other cells. The lack of genes encoding the envelope proteins, as 
well as additional modifications in the viral genome, abolishes the possibility of transduced 
cells being able to produce viable viruses [reviewed in 132]. 
All of the strategies mentioned above have both positive and negative properties. Random 
plasmid integration is cheap and does not require any safety precautions, but is very 
ineffective. MLV retroviruses have a vastly increased efficiency and are easy to produce, 
although they are not able to transduce non-dividing cells, while lentiviral vectors can also 
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infect non-dividing cells [reviewed in 132]. Since viruses released from the packaging cells 
are theoretically capable of infecting all human cells, including those of the person 
performing the transduction, there are safety issues involved when transducing cells. 
3.1.9. Conditional shRNA expression 
The constitutive and ubiquitous expression of shRNAs suffers from limitations when it comes 
to the study of gene functions involving cell survival, growth and development. The reason 
for this is that the selection of transduced cells into a pure cell population typically takes 
several days from the time of the transduction. Within this time frame, the effects of the 
shRNA will have begun. This has prompted the construction of inducible gene silencing 
systems based on conditional RNAi expression. In such systems, the expression of shRNA 
will remain shut off until some sort of signal turns the expression on. In some systems, this 
expression is reversible. 
There are several approaches for achieving conditional expression of shRNA. 
Recombination 
In the Cre/lox (Cyclization recombination/locus of X over P1) system, the shRNA is generally 
expressed from a polIII promoter. The complete shRNA, however, is separated from the 
promoter by a gene sequence flanked by two lox recombination sites. This site is recognised 
by the recombinase enzyme Cre, which will excise the DNA between the two lox sites. This 
recombination will result in transcription of the intact shRNA [135-138]. The advantage of 
this system is that there is no background expression of shRNA until Cre is present and that 
Cre only needs to be present for a short period to achieve permanent shRNA transcription. 
The Cre/lox system can also be used to shut down the expression of shRNA. Here, the 
promoter is placed between two lox sites, which will then be removed by recombination by 
the addition of Cre [138]. A similar system uses the yeast-derived recombinase FLP and its 
recognition site FRT [139]. The main disadvantage of both systems is that once the 
recombination has taken place, it is impossible to reverse it.  
The Tet-inducible system 
The most commonly used system for achieving conditional regulation of shRNA expression is 
based on Tetracycline (Tet) -inducible systems. There are three components necessary for the 
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functioning of this system: The constitutive expression of a Tet-repressor (TetR), a plasmid 
allowing the inducible expression of RNA through a promoter containing a TetR-binding 
sequence named Tet-operator (TetO) and the inducer Tet or one of its derivates, usually 
Doxycycline (Dox). TetR has a high affinity to the TetO, and thus binds tightly to DNA 
strands containing its sequence. The Tet-inducible system was originally developed in polII 
promoters and later adapted to polIII promoters in order to control the expression of shRNA 
[140]. An inducible polII promoter is minimal, meaning that sequences binding 
enhancers/activators necessary for transcription initiation are replaced. Instead, a Tet-
Responsive element (TRE), which contains seven TetO sequences linked to a short stretch of 
sequences containing the PolII transcriptional start site of the CMV promoter, is added [141]. 
TetR is then fused to an activator, which recruits RNA polII to a minimal polII promoter and 
initiates transcription. In the Tet-Off system, the addition of Dox releases TetR and its 
activator from the TRE, turning the transcription off [141]. In Tet-On systems, the activator 
has four amino acids in the TetR moiety that are reversed, giving it the reverse phenotype. 
Here, Dox is required for the binding of TetR and the addition of Dox recruits the activator 
complex, thus turning gene expression on [142]. Of the two, Tet-Off is regarded as the most 
effective system [143]. 
Since PolIII promoters produce RNAs without 3’ polyA tails and 5’ end caps that are able to 
interact directly with exp5 and Dicer, they were the first promoters used for the stable 
expression of shRNAs. It is the U6 and H1 promoters which have been utilised for inducible 
expression via an adapted Tet-off system. Both the U6 and H1 promoters are extremely 
compact, and have three essential domains: the distal sequence element (DSE), the proximal 
sequence element (PSE) and the TATA box. The PSE and the TATA box are binding sites for 
the RNA polymerase itself, while the DSE binds the transactivators necessary for activation 
of the polymerase [144]. The activity of the promoters relies on a correct spacing between 
these elements and the transcription start, while the sequence between them is of lesser 
importance [145]. These intermediate sequences can be adapted to possess a TetO, one 
upstream and one downstream of the TATA box. TetO sequences placed upstream of the PSE 
and in the proximity of the DSE, severely impair transcription from the promoter [146]. When 
the inducer is absent, the TetR will bind to the TetO, thereby sterically preventing binding of 
the polIII. The addition of the inducer leads to a conformational change of TetR into a 
configuration not able to bind to the TetO. This allows polIII to bind and transcription to take 
place (Figure 3). There are two TetOs that have been used extensively in PolIII-inducible 
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promoters, the TetO1 and TetO2 [147]. Several combinations of the two TetOs in US, DS or 
both positions have been described for both the H1 and U6 promoters [140, 148-151]. The 
general conclusion is that one operator alone is not sufficient for achieving tight regulation of 
the promoter in an uninduced state. In addition, it seems as though the TetO2 operator is the 
most effective in terms of suppression [149]. In Paper I, we compared the tightness and 
efficiency in a number of previously described inducible U6 and H1 promoters in several 
different human cell lines, in addition to describing an H1 promoter containing two TetO2s 
for the first time [118]. It was concluded that overall the newly designed promoter performed 
better than the remaining promoters, including the similar U6 promoter containing two type 2 
TetOs. The H12O2 promoter presented a very low background in an uninduced state and up 
to 90% gene suppression after the addition of the inducer Dox. 
 
 
Figure 3: Conditional expression of shRNA from a PolIII promoter. When the inducer Dox is absent, 
TetR is bound to the TetO, thereby sterically obstructing the binding of polIII to the promoter. Dox 
induces a conformational change of the TetR into a form with a low affinity to the TetO. This leads to the 
dissociation of TetR from the promoter, allowing PolIII to transcribe the shRNA. 
The U6 RNA polIII promoter has also been modified to an inducible version following the 
same principles as polII promoters. Here, the DSE was replaced by a TRE, and TetR fused to 
the activator normally binding to the DSE [152, 153]. 
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Following the discovery of shRNA-mir, which are transcribed by polII, the original Tet-
inducible polII promoters returned to the field of RNAi [112, 154]. Here, it was shown that 
these vectors presented tight regulation, high penetrance and high efficiency, even in single 
copy levels of the inserted cassette. Although the Tet-Off system has been previously 
regarded as superior to the Tet-On system, the transcriptional activator originating from the 
Tet-On system has been improved using viral evolution as a tool to better adapt it from its 
original host, E. coli, to mammalian systems [155]. The resulting activator has been utilised in 
inducible shRNA systems to yield improved gene suppression [156]. Two shRNAs targeting 
different mRNAs from the same promoter were also expressed, thereby acquiring the ability 
to knockdown two genes simultaneously. 
Ecdysone 
The ecdysone system is similar to the Tet system in its principle of function. The ecdysone 
receptor is fused to an activator, and binds to the Gal4-binding sequences. It uses ecdysone-
analogs as inducers, and the addition of the inducer releases the receptor along with its 
activator from the minimal promoter, thereby turning transcription off. The system is 
functional in both polII and polIII promoters [157, 158].The vector integration site strongly 
influences expression, which requires careful selection of effective clones. Additionally, 
ecdysone is a steroid prohormone, and activation of its receptor could trigger endogenous 
gene expression in target cells [reviewed in 159]. 
3.1.10. Off-target effects 
Off-target effects of RNAi are defined as consequences that arise from any effect other than 
the intended gene suppression. The off-target effects are divided into two main categories: 
specific and non-specific. 
Specific off-target effects 
Specific off-target effects arise as a result of a full or partial complementarity between the 
passenger or guide strand towards any unintended target. In order to achieve target cleavage 
through the action of Ago, it is necessary to have perfect complementarity extending through 
at least 13 nt of the strand mounted in the RISC [160]. A BLAST search of the transcriptome 
of the species investigated will quickly expose siRNAs harbouring unspecific 
complementarity of this degree, allowing for those siRNAs to be discarded. As a consequence 
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of this, there is more concern regarding partial mismatches, particularly when including nt 2 – 
8 counted from the 5’ end of the guide strand. These nucleotides form the seed sequence that 
allows the guide strand of the siRNA to function as a miRNA [61]. It is has been shown that 
the off-target effects of siRNAs are strongly biased to occur from ~7 nt complementarity 
between the “seed sequence” of the guide strand and the 3’ UTR of the unintended targets and 
that the unintended target sequences are often conserved in several mRNAs [161]. The 
magnitude of the regulation of transcripts targeted as siRNA off-targets is generally less than 
twofold, which is similar to that of miRNAs [161, 162]. This suggests that siRNAs are prone 
to target unintended miRNA seed sequences of ~7 nt. Because of this, there could be a 
discussion as to whether the less than twofold regulation realised by off-target siRNAs has 
any biological relevance. Adverse unintended phenotypes arising from such off-target effects 
have been described [161, 163]. There is no algorithm that can significantly eliminate 7-8 nt 
matches in the transcriptome of a species; therefore, some off-target effects are likely to occur 
when using any form of RNAi-mediated gene silencing, and there are developed algorithms 
that try to minimize off-target effects [164-166]. 
Non-specific target effects 
Non-specific target effects are effects that do not result from direct interaction between an 
RNAi construct and an mRNA target. This includes immune-responses as a result of defence 
mechanisms triggered against exogenous RNA, any effect related to the delivery vehicle in 
addition to any effects arising from saturation of the miRNA pathway. 
Initially, it was thought that RNA duplexes shorter than 30 nt were small enough to evade 
stimulation of the interferon response [9]. However, this assumption has been questioned, as 
activation of immune responses resulting from the introduction of small siRNAs has been 
described [167, 168].  The 13 Toll-like receptors (TLRs) are a class of proteins that recognises 
signs of infection and activates the innate immune system. Of these, the ones most relevant 
for activation as a result of RNAi are TLR3, which recognises the duplex form of siRNA, and 
TLRs 7 and 8, both of which are activated either by the duplex or its corresponding single 
strand [169-171]. TLR receptors are often concentrated in endosomes, thus transfection 
methods utilising cationic lipids enhance the immune response [171]. In contrast, ShRNAs are 
less likely to induce an immune response since they are presented from a DNA plasmid, 
thereby avoiding the dsRNA activation of TLR3. In addition, the 5’ ends of shRNA, which 
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are produced endogenously, seem to be less immunogenic than corresponding 5’ ends of 
exogenous siRNAs [101, 172]. Chemical modifications of siRNAs can reduce their 
immunogenicity [reviewed in 173].  
RNAi uses the miRNA pathway in order to exert its effect. As a result, any exogenous RNAi 
effector competes with endogenous miRNAs for access to the miRNA machinery. ShRNAs 
are entering the miRNA pathway at a higher level than siRNAs (Figure 2), and are therefore 
competing with miRNAs in more steps than siRNAs. The most rate-limiting step in the 
miRNA pathway seems to be the export of pre-miRNA from the nucleus to the cytoplasm by 
exp5, and shRNA expression is shown to interfere with endogenous miRNAs as a result of 
saturation from this step [174]. Also, the sustained expression of shRNAs stably delivered to 
liver cells in adult mice has been revealed to severely downregulate the expression of 
endogenous miRNA [175]. This was demonstrated to be a result of saturation due to 
Exportin5 activity as well as the activity of Ago2 in RISC [176]. By expressing the shRNAs 
from a miR backbone, the toxicity of shRNAs has been shown to be diminished [177]. One 
group has proposed that siRNAs are unable to saturate the miRNA pathway by showing that 
the expression of three different miRNAs in liver cells did not change when siRNA-mediated 
gene suppression was utilised [178]. Nonetheless, it has also been shown that both shRNAs 
and siRNAs compete not only with each other, but with endogenous miRNAs for 
incorporation to RISC [179]. In addition, it has been proposed that transfected small RNAs 
have a global effect on genes under the control of endogenous miRNAs [180]. Here, the 
results from 151 published experiments based on the transfection of either siRNA or miRNA 
into cells in culture were analysed. A statistical analysis of the published mRNA profiling or 
protein mass spectrometry revealed that in the majority of the experiments, endogenous 
mRNAs containing targets of miRNAs with high endogenous expression were upregulated as 
a result of competition from exogenous mi/siRNAs. 
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3.2. Neuroblastoma 
3.2.1. Embryonal development and neoplasms 
The development of an embryo begins with a single fertilised egg. Countless cell divisions of 
this perfect stem cell eventually lead to the generation of organs and every other component 
of the organism. After the first few cell divisions of the zygote, it is already apparent that cell-
cell interactions start to decide the fate of the daughter cells [181]. From this point on, the 
development of the embryo is a process comprised of strictly controlled proliferation and 
differentiation signals. In the early embryo, there is a majority of strong mitogenic signals that 
limit the ability of cells to exit the cell cycle. During embryonal development, changes in the 
concentration of key regulatory signals promote the exit of the cell cycle and the onset of 
differentiation for the targeted cells. In normal development, the signals indicating 
proliferation or differentiation are under tight control, though in tumour growth this control is 
lost. If a strong mitogenic signal expressed transiently during development achieves 
constitutive expression, it acts as an oncogene. Alternatively, if a protein involved in 
signalling pathways leading to cell cycle exit and differentiation loses its function, it may no 
longer act as a tumour suppressor. Tumours originating from tissues that normally proliferate 
only in a developing embryo are known as embryonal tumours. If the tumour arises from 
primitive precursor cells, it is given the suffix blastoma. These tumours can arise in various 
parts of the body and include medulloblastoma in the brain, neuroblastoma in the sympathetic 
nervous system, retinoblastoma in the eye, Wilms’ tumour (nephroblastoma) in the kidney, 
hepatoblastoma in the liver and embryonal rhabdomyosarcoma in soft tissue. These tumours 
are very rare after childhood, and most commonly occur during the first years of life. 
3.2.2. Development of the sympathetic nervous system 
On day 19 of the embryo, the neural plate starts to form on the ectoderm of the embryo. The 
edge of the neural plate is defined by neural crest precursors, and as the neural plate folds in 
on itself, the neural crest precursors from each outer edge join and form the dorsal part of the 
newly developed neural tube. The neural tube is developing to form the central nervous 
system, while the now mature neural crest cells start to migrate from the dorsal part of the 
neural tube into several areas of the embryo [reviewed in 182]. Neural crest cells are the 
origin of several cell lineages: cranial (e.g. forming facial bones), vagal and sacral (e.g. 
parasympathetic neurons), cardiac (contributing to the development of the heart) and trunk 
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neural crest-derived cells (e.g. melanocytes and the sympathetic nervous system, including the 
adrenal medulla) [183].  
Trunk neural cells destined to form the sympathetic neural system are of the sympathoadrenal 
lineage. These migrating sympathetic neuroblasts arrange themselves alongside both sides of 
the neural tube before they start forming chains of sympathetic ganglia. As internal organs are 
being developed, sympathetic fibres formed by axonal outgrowth from the ganglia reach out 
to and connect them to the sympathetic nervous system in a process known as innervation 
[183]. 
The differentiation from neural crest precursors at the neural plate to non-dividing neural cells 
in the sympathetic nervous system requires involvement of a large amount of signalling 
pathways. The formation of both the neural plate and neural crest precursors are dependent on 
expression levels of the bone morphogenetic protein (BMP) pathway, the fibroblast growth 
factor (FGF) pathway and the Wnt signalling pathway [reviewed in 184]. As the neural tube is 
formed, the neural crest precursors mature to neural crest cells before going through an 
epithelial to mesenchymal transition, in which they shed from the neural tube and start 
migrating. This process is largely governed by Wnt signalling, and leads to expression of a set 
of genes known as neural crest specifiers. As the migrating neural crest cells reach their final 
target, they start differentiating, while many of the neural crest specifiers are downregulated 
[reviewed in 185]. Neural crest cells destined for the sympathoadrenal lineage demonstrate 
increased BMP signalling [186, 187]. As they further mature, they start expressing enzymes 
required for the synthesis of noradrenalin, e.g. tyrosine hydroxylase [188, 189], and as they 
acquire a neuronal fate they start expressing neurofilaments, neuron-specific tubulin and other 
neuronal markers [187, 190, 191]. After the acquisition of neuronal traits, the 
sympathoadrenal cells undergo a second migration step away from the dorsal aorta to form 
the secondary sympathetic ganglia, the prevertebral ganglia and the adrenal medulla in a 
process that probably involves FGF and NGF signalling [192]. This differentiation process 
also involves a myriad of transcription factors required to be expressed at the correct time and 
in the correct amount [reviewed in 192]. Among these are MYCN, which is expressed in 
migrating neural crest cells [193]. It seems as if MYCN is necessary for keeping the cell in a 
migrating state, in addition to being an important signal for committing the neural crest cells 
where it is expressed towards the sympathoadrenal lineage [193]. Like many of the neural 
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crest specifiers, MYCN expression is turned off as the neural crest cells reach their final 
destination and differentiate towards their ultimate phenotype [194]. 
As the neural crest cells differentiate and spread throughout the embryo in order to form the 
sympathetic nervous system, the number of cells in each differential stage must be under strict 
control. Developmental apoptosis is crucially important in this matter, and progenitor cells of 
all stages are prone to enter apoptosis if given the appropriate signals [reviewed in 195]. For 
instance, it has been proposed that during normal development neuronal progenitor cells 
compete with each other for access to NGF, and as NGF becomes limited, the losers will enter 
apoptosis via a pathway that includes the tumour suppressor KIF1Bβ [196].   
3.2.3. From neuroblasts to neuroblastic tumours 
Being an embryonal tumour, neuroblastoma is regarded as a consequence of the disordered 
normal development of cells from the sympathoadrenal lineage of neural crest cells [197]. As 
described above, the cells of the sympathetic nervous system originate from neural crest cells, 
going through an epithelial to mesenchymal transition, before migrating as single cells until 
they reach their destination. A second migration step is then initiated in order to complete the 
sympathetic nervous system. Migrating mesenchymal cell types are often related to cancer 
[reviewed in 198], and it is not difficult to imagine that the failure of neuroblasts to exit the 
mesenchymal mode and alternatively returning to it, could result in the development of 
malignant neoplasms.  
Neuroblastic tumours (i.e. neoplasms of the sympathoadrenal lineage) can arise anywhere in 
the sympathetic nervous system, although the majority of primary tumours appear in the 
abdomen, with a major site being the adrenal medulla. Other common sites include the neck, 
chest and pelvis [199]. Neuroblastic tumours can be divided into three categories based on 
their morphologic features: Ganglioneuroma, ganglioneuroblastoma and neuroblastoma [200]. 
Ganglioneuromas appear as clusters of mature neurons surrounded by a stroma of Schwann 
cells, while neuroblastoma cells appear as undifferentiated tumours consisting of small, round 
neuroblasts. Ganglioneuroblastomas are the intermediate of the two [200]. Ganglioneuromas 
are well encapsulated benign tumours not capable of invading or metastasizing. 
Ganglioneuroblastomas are generally benign, while neuroblastoma often appear as a very 
aggressive cancer which commonly metastasizes [200].  
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3.2.4. Neuroblastoma – the disease  
Neuroblastoma is not a common disease. In Sweden, the incidence over a period of 27 years 
was 1 case/100,000 children below the age of 15 years [201]. Despite being rare, 
neuroblastoma accounts for 7-10% of all diagnosed childhood cancers and 15% of all 
childhood cancer deaths [199, 202]. Neuroblastoma is divided into risk groups based on 
criteria such as age of the patient at diagnosis, International Neuroblastoma Risk Group 
(INRG) tumour stage and MYCN copy number (Table 1) [203, 204]. Patients in the low and 
intermediate risk group show fairly good prognosis, while the event-free survival (EFS) rate 
for patients diagnosed with high risk neuroblastoma is less than 50% [203].  
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Table 1: International Neuroblastoma Risk Group (INRG) Consensus Pretreatment Classification 
schema. Pretreatment risk group H has two entries. Blank field = "any"; DI, diploid (DNA index ≤ 1.0); 
HDI, hyperdiploid (DNA index > 1.0 and includes near-triploid and near-tetraploid tumours); very low 
risk (A-C, 5-year EFS > 85%); low risk (D-F, 5-year EFS > 75% to ≤ 85%); intermediate (intermed) risk 
(G-J, 5-year EFS ≥ 50% to ≤ 75%); high risk (K-R, 5-year EFS < 50%). GN, ganglioneuroma; GNB, 
ganglioneuroblastoma; Amp, amplified; NA, not amplified; L1, localised tumour confined to one body 
compartment and with absence of image-defined risk factors (IDRFs); L2, locoregional tumour with 
presence of one or more IDRFs; M, distant metastatic disease (except stage MS); MS, metastatic disease 
confined to skin, liver and/or bone marrow in children < 18 months of age; EFS, event-free survival 
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Neuroblastoma has a high rate of spontaneous regression. The total amount of neuroblastomas 
that are detected clinically and regress without any treatment is approximately 5-10% [202]. 
This clinical phenotype (INRG MS stage, risk group C) is mainly seen in infants below the 
age of 18 months, and is presented with small localised primary tumours with metastases in 
the liver, skin or bone marrow. It is assumed that the cause of these naturally regressing 
tumours is the delayed activation of differentiation or apoptosis pathways [202]. In fact, it is 
shown that microscopic neuroblastic nodules occur uniformly in all fetuses, peaking between 
17 and 20 weeks of gestation, and then gradually regressing by the time of birth [205, 206]. 
Additionally, neuroblastomas within INRG C rarely, if ever, evolve into any of its malignant 
forms, which indicates that the malignant forms of neuroblastoma affecting children older 
than 18 months are of a distinct type [202]. Neuroblastoma often contains a range of genomic 
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aberrations. Neuroblastomas that are prone to spontaneous regression are often characterised 
by a mitotic dysfunction, resulting in a hyperploid or near triploid phenotype with few 
structural abnormalities [207, 208]. On the other hand, neuroblastomas in patients one year or 
older are often characterised by a near-diploid or near-tetraploid karyotype in addition to 
numeral structural abnormalities [207, 208].  
The most frequent aberration in neuroblastoma is gain of chromosome 17q, which is found to 
be present in a majority of tumours [209, 210]. In neuroblastoma, it seems as if chromosome 
17q gain is a result of translocation from several other chromosomes [211]. A frequent 
aberration is an 11q loss of heterozygosity (LOH), which is a prognostic marker for poor 
outcome in neuroblastoma without MYCN amplification [212, 213]. Another frequent allelic 
loss occurs on chromosome 1p [214]. Deletions in chromosome 1 are also found more 
frequently in patients with advanced disease, but LOH on 11q and 1p rarely occurs in the 
same tumours [202, 215]. Many tumours with 1p LOH also contain an amplification of the 
2p24 locus, which is the site of the proto-oncogene MYCN [216, 217]. MYCN amplification 
rarely exists without 1p LOH, whereas not all cases of 1p LOH contain MYCN amplification, 
an observation that suggests that 1p LOH is a prerequisite for MYCN amplification [202]. 
Patients with 1p LOH and eventual MYCN amplification are typically 1-5 years old with 
advanced stage, rapidly progressive and often fatal neuroblastoma, while patients with 11q 
LOH neuroblastoma are often older, with an advanced stage of disease that slowly progresses 
and is often fatal [202]. 
3.2.5. Expression of MYCN in neuroblastoma 
MYCN is a member of the MYC gene family of transcription factors, all of which initiate 
transcription in similar ways. The MYCN transcription factors form an active complex when 
heterodimerised with its partner MAX [218, 219]. Both MYCN and MAX contain DNA 
binding motifs, and the active protein complex can initiate transcription when bound to its 
DNA binding sites. The most frequently targeted DNA sequence is the E-box motif (5’-
CAC(A/G)TG) [220-222]. In addition, H4-K3 methylation of a promoter region has been 
shown to be an indicator for MYCN/MAX binding [223]. MAX can also dimerise with MAD, 
and the resulting complex also has an affinity towards E-boxes, but functions as a 
transcriptional repressor instead of an activator [224-226]. MYCN is also shown to be 
involved in transcriptional repression in neuroblastoma [227]. Here, MYCN has been 
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demonstrated to act as a bridge between the DNA binding protein Sp1 and the repressor 
histone deacetylase (HDAC), resulting in transcriptional repression of tissue transglutaminase 
(TG2). 
The amplification of a gene is a result of chromosomal rearrangements leading to an increased 
copy number of the amplified gene. Amplification of MYCN was first observed in 1983, when 
it was shown that MYCN could be amplified up to 140 fold [228]. It seems as if all copies of 
the amplified gene contribute to the expression of MYCN and that the increased gene number 
is the reason for the high MYCN mRNA expression in MYCN amplified (MNA) 
neuroblastoma cells [217, 229]. Generally speaking, it seems that levels of mRNA resulting 
from MYCN amplifications reach a 40-60 fold increase in comparison to single copy cell lines 
with a low expression of MYCN, and that the increase in mRNA level is not always 
proportional to the number of gene copies [230]. 
As described above, MYCN is naturally expressed in neural crest cells of the sympathoadrenal 
lineage, which is assumed to be important for maintaining the cells in a migrating state [193]. 
In cancer terminology, mesenchymal cells that are able to migrate are closely related to a 
malignant phenotype, so it is therefore not surprising that a protein devoted to maintaining 
this phenotype is a potent oncogene. Indeed, MYCN amplification is one of the most 
prominent prognostic indicators for a bad outcome in neuroblastoma [203]. MYCN has been 
shown to be causally involved in tumourigenesis and tumour progression, as transgene mice 
expressing MYCN in the neuroectoderm develop neuroblastoma several months after birth 
[231].  
3.2.6. MYCN targets 
The exact mechanism MYCN uses to mediate its oncogenic effect is still largely unknown, but 
some pathways are emerging as likely candidates for executing the malignant potential of 
MYCN. Here follows a brief description of a few direct targets of MYCN:  
MYCN expression has been shown to increase proliferation by shortening the time used to 
progress through the cell cycle [232]. E2F1-3 are transcription factors which mainly regulate 
the expression of numerous genes necessary for the S-phase of the cell cycle such as 
thymidine kinase, dihydrofolate reductase (DHFR), DNA Polα and cell division cycle 6 
(cdc6). Thus, active E2F1-3 pushes the cell into the S-phase [reviewed in 233].When E2F1-3 
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are bound by hypophosphorylated retinoblastoma protein (RB), it is inactive, and the cell 
remains in the G1 phase. Phosphorylation of RB through the cyclin D/CDK4/6 complex 
removes RB from the RB/E2F complex, thereby releasing active E2F. Several possible 
MYCN targets engaged in the cell cycle progression are probably functioning through 
regulation of the E2F1-3 transcription factors [reviewed in 234]. E2F1 has been demonstrated 
to be a transcriptional target of MYCC, and there are indications that MYCN also regulates 
E2F1 expression, while at the same time E2F1-3 activates the expression of MYCN itself 
[reviewed in 234]. 
MYCN is known to increase the susceptibility of cells entering apoptosis following cellular 
stress such as DNA damage, survival factor withdrawal, substrate detachment and hypoxia 
[reviewed in 235]. p53 is known as the guardian of the genome, and is involved in DNA 
repair and/or initiation of apoptosis as a result of extensive DNA damage. It has recently been 
reported that p53 is a direct transcriptional target of MYCN [236], and this finding suggests a 
mechanism for the MYCN-driven p53-dependent apoptosis necessary for achieving control of 
rapidly dividing neuroblasts in normal development. However, MYCN is also a 
transcriptional activator of MDM2, which is a negative regulator of p53 [237].  
Bmi1 is a transcriptional repressor required for the self-renewal of stem cells of the central- 
and peripheral nervous system [238], and are highly expressed in a vast majority of primary 
neuroblastoma tumours regardless of MYCN status [239]. Ochiai et al. have shown that its 
promoter contains E-box sequences and that as a result, Bmi1 is a direct transcriptional target 
of MYCN [240]. In addition, they have shown that Bmi1 directly downregulates several 
tumour suppressors in neuroblastoma, among them KIF1Bβ and TSLC1, both of which have 
been correlated to a bad prognosis when downregulated [241, 242]. KIF1Bβ is an important 
signal for apoptosis of neural progenitor cells when NGF access is reduced [196]. The exact 
function of TSCL1 in neuroblastoma is not known, but it is suspected that it demonstrates an 
antiproliferative and/or proapoptotic activity [241]. 
3.2.7. Targeted MYCN downregulation 
Given that MYCN is a strong oncogene being expressed naturally primarily in embryonal life 
only, it has long been regarded as an ideal candidate for targeted therapy [243]. The first 
approaches for a targeted reduction of MYCN expression were conducted by using standard 
antisense technology [244]. Here, it was found that repression of MYCN expression leads to 
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reduced proliferation and differentiation towards a more neuronal phenotype in a MNA 
neuroblastoma cell line. Peptide nucleic acids (PNA) are nucleic acid analogues in which the 
sugar backbone is replaced by a synthetic peptide backbone. The resulting mimic is 
uncharged, and thus binds with greater affinity to complementary nucleic acids (both DNA 
and RNA) than nucleic acids. Because there are no naturally occurring PNAs, they are not 
targets of enzymatic degradation [reviewed in 245]. PNAs have successfully been used for 
targeted downregulation of both MYCN mRNA [246, 247] and the MYCN gene at the DNA 
level [248]. Although fairly effective and selective, PNAs are expensive to design and 
synthesise. As RNAi has evolved as a superior tool for targeted gene suppression, transient 
siRNA-based MYCN-knockdown has also been used to show reduced cell growth, induced 
differentiation and induced apoptosis in MNA neuroblastoma cells [249, 250].  
The SHEP Tet21N system has been evolved for mainly studying MYCN-related cell cycle 
effects [232]. Neuroblastoma cell lines established in culture appear to be heterogenous, and 
can be divided into three different subgroups: neuroblastic (N), substrate adherent (S) and 
intermediate (I) cell types. N-type cells appear as being small, rounded and loosely attached, 
with numerous neurite-like processes. The S-type is larger, flatter and more strongly substrate 
adherent, and appears to be fibroblastic/epithelial and do not express any neuronal markers. 
The I-type appears as a morphological intermediate between the N- and S- types, and can be 
induced to differentiate towards both subgroups [251, 252]. In the SHEP Tet21N system, a 
MYCN gene is stably transfected into an S-type clone derived from the I-type SKNSH 
neuroblastoma cell line [232]. In this Tet-Off system, the expression of MYCN can be turned 
off by adding the inducer tet (confer with Chapter 3.1.9 above).  
3.2.8. MiRNA in neuroblastoma 
MiRNAs are regarded as vital contributors to the pathogenesis of a wide array of tumours [92, 
93]. The first expression profiling study indicated that miRNAs were differentially expressed 
in various genomic subtypes of neuroblastoma [253]. It has now been established that MNA 
and other chromosomal imbalances lead to vast dysregulation of the miRNA expression in 
primary neuroblastoma tumours [reviewed in 254]. As mentioned above, MYCN is a 
transcription factor that mainly induces the transcription of genes with E-boxes in the 
proximity of their promoter. MiRNAs are also expressed from RNA polII promoters, and 
MYCN has been shown to regulate the expression of miRNAs [255]. MiRNAs also have the 
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potential to act as both tumour suppressors and oncogenes in neuroblastoma [reviewed in 
254].  
An example of a miRNA acting as a tumour suppressor is miR-34a, which is frequently 
downregulated in primary neuroblastomas [256]. MiR-34a is located in a region of 
chromosome 1p36 that is often deleted in neuroblastoma, and is shown to have an anti-
proliferative effect when overexpressed in neuroblastoma cell lines [256]. Oncogenes found 
to be targets of miR-34a are the transcription factor E2F3 and MYCN [256, 257].  
The miR-17 family of miRNAs are expressed from three different miRNA clusters located on 
three different chromosomes: The 17-5p-92 (miR 17, -18a, -19a, -20a, -19b1 and -92a1), the 
miR 106a-363 (miR 106a, -18b, -20b, -19b2, -92a2, -363) and the miR 106b-25 (miR 106b, -
93, -25) [258]. The miR-17 family is shown to be vital for development of the embryo and 
initiating of the differentiation of pluripotent stem cells [259]. All three clusters harbour E-
box motifs in its proximity [260], and all clusters are shown to be directly regulated by 
MYCN [261, 262]. Several members of the miR-17 family, especially those of the 17-5p-92 
cluster, are shown to act as potent oncogenes in neuroblastoma cells [261, 262]. This is a clear 
indication that at least parts of the oncogenic effect of MYCN are mediated directly through 
the transcriptional activation of miRNAs. MYCN is primarily a transcriptional activator, and 
as described above, only rarely acts as a transcriptional repressor. So far, no miRNA has been 
shown to be directly downregulated by MYCN. However, miRNAs can be inversely 
correlated to MYCN expression as a result of indirect mechanisms [253].  
In paper III, we document for the first time that miR-92b might be activated by MYCN. We 
also suggest that most miRNAs inversely correlated to MYCN are probably involved in 
differentiation.  
3.2.9. DKK3 and neuroblastoma 
In neural crest development, the BMP-, FGF- and Wnt pathways are the main regulators of 
neurulation and the subsequent formation of neural crest cells [184]. The disturbance of these 
early developmental pathways has been shown to be involved in several other forms of 
cancers [263-265], and these pathways are therefore interesting to study in neuroblastoma as 
well. In the canonical Wnt pathway, a Wnt protein binds to its trans-membranous receptor 
frizzled and the co-receptor low-density lipoprotein receptor-related protein 5 (LRP5)/LRP6. 
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This leads to activation of an intracellular pathway that ultimately leads to the accumulation 
of the protein β-catenin in the nucleus where it activates the T-cell factor/lymphocyte 
enhancer factor (TCF/Lef) family of transcription factors. Activation of the canonical Wnt 
pathway regulates a wide array of biological effects, including activation of cell cycle 
progression and proliferation, inhibition of apoptosis, regulation of embryonic development, 
cell differentiation, cell growth and cell migration [reviewed in 266]. Wnt signalling can also 
activate independent non-canonical pathways, the two most described being: 1. The Wnt/Ca2+ 
pathway, which activates the protein kinase C and the Ca2+- calmodulin dependent protein 
kinase II, 2. the cytoskeleton pathway, which regulates the organisation and formation of the 
cytoskeleton and planar cell polarity [reviewed in 267]. There are also several other less 
described and characterised non-canonical Wnt pathways [268]. 
The family of dickkopf proteins (DKK1-4 and Soggy) is a group of secreted glycoproteins 
primarily regarded as inhibitors of the Wnt pathway [269]. While DKK1 and DKK2 
inactivate Wnt signalling by obstructing the binding between LRP5/6 and Wnt ligands, DKK3 
is not able to interact with LRPR6 [270]. DKK3 has been revealed to have distinct roles in the 
modulation of the Wnt pathway, depending on the cell types being studied. DKK3 increases 
Wnt signalling in mouse glia cells and HEK293 [271], but inhibits Wnt signalling in 
pheochromocytoma cells from rat (PC12) [272] and osteocarcinoma (Saos-2) cells [273]. 
Since DKK3 does not bind to the LRPR5/6 receptors, little is known about the molecular 
basis for DKK3-dependent Wnt inhibition. DKK3 does however bind to the membrane bound 
Wnt inhibitor Kremen, and Nakamura and Hackam have proposed that DKK3 potentiates Wnt 
signalling by facilitating a relocation of Kremen from the cell membrane by endocytosis 
[270]. 
DKK3 is an established tumour suppressor shown to be downregulated in a range of tumour-
derived cells, e.g. Saos-2, hepatoblastoma, acute lymphoblastic leukaemia and non-small-cell 
lung cancer [reviewed in 269]. The downregulation of DKK3 is often a result of 
hypermethylation of the DKK3 promoter [274, 275], whereas the overexpression of DKK3 has 
been demonstrated to suppress tumour growth of, e.g. Saos-2 [273], prostate cancer [274, 
276] and neuroblastoma [277]. 
It has been shown that there is an inverse correlation between the expression of MYCN and 
the Wnt antagonists DKK1 and DKK3 in neuroblastoma [278, 279]. In particular, the 
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correlation between DKK3 and MYCN has been proven to be a strong one by Koppen et al. 
[277]. Here, it was documented that DKK3 is a marker for neuroblastic tumour maturation 
and that it is indirectly downregulated by MYCN. In paper IV, we show that DKK3 is 
repressed by miR-92a, miR-92b and let-7e, all of which are MYCN–regulated miRNAs [261, 
Paper III].  
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4. Aims 
Neuroblastoma with MYCN amplification represents the most aggressive form of this disease. 
Although MYCN has been regarded as the most prominent prognostic indicator for bad 
outcomes, the role of MYCN in neuroblastoma tumourigenesis remains largely unknown. The 
silencing of MYCN and its downstream targets are attractive goals for targeted therapy, but 
very little is known about the long-term effects of MYCN silencing of MNA neuroblastomas. 
The main aim of this study was to establish an efficient knockdown of MYCN in MNA 
neuroblastoma cell lines in a stable and inducible manner and to use these cell lines to obtain 
further knowledge of MYCN and its downstream targets, including miRNAs. 
Paper I 
Evaluate available options for inducible expression of shRNA. Design and establish an 
inducible promoter system that is tight when uninduced, and which has a high expression of 
shRNA when induced. In addition, the vector system should allow easy incorporation of any 
desired shRNA. 
Paper II 
Establish MNA cell lines with stably integrated shRNA expression targeting MYCN under 
inducible control using the promoter system designed and developed in Paper I. 
Paper III 
Use shRNA to silence MYCN and study the differential expression of miRNA expression both 
before and after knockdown. Investigate the biological effect of the miRNA with the most 
pronounced change in expression. 
Paper IV 
Previous data published by others has suggested that the possible tumour suppressor DKK3 
was regulated by MYCN in an indirect manner. We aimed to use the miRNA profiling data 
obtained in Paper III to search for MYCN-regulated miRNAs with predicted targets in the 
DKK3 3’ UTR, as well as investigating whether MYCN regulates DKK3 through miRNAs.  
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5. Discussion 
5.1. Papers I and II 
5.1.1. Brief description of the studies 
In Paper I, we compared the properties of six polIII promoters with tet-inducible expression. 
Four of the promoters were previously described by others [140, 148, 149, 280], while two 
versions of the H1 promoter were novel designs. The tightness and expression efficiency of 
the promoters in an induced and uninduced state were compared using a luciferase reporter 
system. Here, cells containing a stable expression of TetR were transiently cotransfected with 
three plasmids: a plasmid with a constitutive expression of the firefly luciferase reporter, a 
plasmid with a constitutive expression of β-galactosidase for normalisation and a plasmid 
expressing an anti-luciferase shRNA expressed from the promoter being evaluated. Luciferase 
activities were measured and normalised against β-galactosidase expression. The experiments 
were performed with the absence of the inducer Dox for an evaluation of tightness, as well as 
in the presence of Dox for an evaluation of transcription efficiency.  
For both U6 and H1 promoters, constructs containing only one tet operator in the promoter 
were unacceptably leaky. Overall, we found the novel H12O2 promoter to perform slightly 
better than the similar U62O2 promoter when directly compared.  
In Paper II, we introduced a shRNA (aMN-1658) that specifically downregulated the MYCN 
protein expression ~90% without any observations of off-target effects. This shRNA was 
inserted into the H12O2 US/DS inducible promoter cassette designed in Paper I before being 
stably transduced to the MNA neuroblastoma cell lines Kelly and SK-N-BE(2) using an MLV 
retroviral delivery system. The resulting RV-1658 cell lines appeared with a similar 
morphology to control cells in an uninduced state. When induced with 1 µg/ml dox, MYCN 
expression was efficiently downregulated, the cells differentiated towards neuron-like cells, 
entered G1 arrest and showed a significantly reduced clonogenic growth. 
5.1.2. Discussion 
The novel H12O2 promoter designed by us was developed by introducing a second TetO2 
downstream of the TATA-box in a commercially available pENTRH1-O2 plasmid 
36 
(Invitrogen). The sequence between the TATA-box and the transcription start (25 bp) can be 
altered without affecting the transcription efficiency of the H1 promoter as long as the spacing 
between the two remains the same [281]. The TetO2 sequence of 19 bp ends with the 
nucleotides AGA, which is a part of the BglII restriction site (AGATCT). The design of the 
H12O2 promoter allows the positioning of a stuffer sequence directly downstream of the 
transcription start site. This stuffer can be removed by BglII restriction enzymes and replaced 
by a properly designed shRNA sequence targeting a desired gene.   
The conditional expression of shRNAs is feasible from both polIII promoters and polII 
promoters. As described above, it seems that conditional expression from polII promoters 
may provide some advantages over polIII promoters such as less off-target effects [177], 
tighter regulation [112, 154] and the possibility of expressing several shRNAs in a 
polycistronic manner [156]. Even so, shRNAs expressed from polIII promoters seem more 
potent than similar shRNAs expressed from polII promoters, thus allowing a higher efficiency 
when the silencing of highly expressed targets is desired [124]. In MNA neuroblastoma cell 
lines, the expression of MYCN mRNAs is generally 40-60 fold higher than in single copy cells 
[230]. As a result of this, the potency of the shRNAs is of great importance when MYCN 
silencing in MNA cell lines is considered.  
In Paper II, we have described a system for the conditional and stable expression of shRNAs 
targeting MYCN in MNA neuroblastoma cell lines. One of the main reasons for developing 
this cell line was the desire to specifically study the long-term effect of MYCN knockdown in 
MNA cell lines. The SHEP Tet21N system is perhaps the most widely used cell system for 
studying the effect of MYCN silencing in neuroblastoma [232]. Here, MYCN is introduced to 
an S-type neuroblastoma cell line normally not expressing MYCN. When S-type 
neuroblastoma cell lines are exposed to the vitamin A metabolite retinoic acid (RA), they 
enter apoptosis, while N-type cells generally differentiate towards a more neuronal phenotype 
[282]. As a consequence, this system is not suitable for studying the effect of MYCN on 
differentiation in neuroblastoma cell lines. The SHEP Tet21N system however has proven 
especially valuable for determining the effect of MYCN on proliferation and apoptosis. 
Traditional antisense technology has previously been used for the stable silencing of MYCN in 
non-MNA neuroblastoma cell lines with a high MYCN expression [283]. Still, antisense 
technology is not efficient enough to successfully silence MYCN in MNA cell lines, as it has 
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been shown that the antisense:sense RNA ratio must be on the order of 1000:1 for obtaining 
antisense-sense duplexes of 50% of the target mRNA [284]. Successful antisense-based 
silencing of MYCN in the IMR-32 cell line has been reported, but here the authors used an 
Epstein-Barr viral approach in which the antisense MYCN expression was magnified by 
episomal replication [285]. Here, the MYCN suppression was significant, though no 
differentiation was observed. Later experiments using siRNAs targeting MYCN have 
demonstrated that IMR-32 differentiates extensively upon MYCN silencing [250]. This 
discrepancy might be a result of off-target effects since it has been shown that MYCN 
antisense RNAs are targets for the interferon pathway in a MNA cell line [286].  
The superior efficiency of shRNA compared to antisense approaches is apparent when 
considering the RV-1658 constructs presented in Paper II. Here, we achieved a specific, 
efficient and conditional downregulation of MYCN in two MNA cell lines as a result of 
shRNA being expressed from a single genomic insert. In addition to this, no off-target effects 
resulting from interferon response were detected. When using any type of small RNA, the off-
target effects most widespread seem to be those resulting from saturation of the miRNA 
pathway [180]. We did not observe any signs of such off-target effects in our study, although 
they cannot be ruled out since these symptoms could be very difficult to detect. 
We chose to use a MLV retroviral system for stably delivering the inducible expression 
cassettes to neuroblastoma cell lines. The inducible promoter described in Paper I can easily 
be gated into a retroviral expression vector, which was then used to transfect the Hek-293 
Phoenix packaging cell line for the synthesis of retroviral particles. The entire process utilises 
vectors and cell lines easily propagated in any lab with suitable facilities, and thus it is 
relatively easy and cost efficient to produce any new shRNAs towards any target in any 
dividing human cell. After induction of the RV-1658 cell lines, it typically took 3-5 days 
before full silencing of MYCN was achieved. As a result of this, the inducible system is not 
optimal for investigating direct targets of MYCN. 
As described in Paper II, we observed minimal amounts of leakage of anti-MYCN shRNA in 
an uninduced state within the time frame the cells were grown in. Nevertheless, some leakage 
is inevitable when Tet-inducible polIII promoters are being used. In our experience, there was 
no significant leakage within the first month after transduction. When we tried to isolate 
single clones of transduced cells, leakage in uninduced cells was evident. After proliferating 
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for approximately 10 weeks, the cells appeared to be morphologically undifferentiated, but 
expressed up to 30% less MYCN than the control cells. Yet, induction led the MYCN levels 
to drop further, which was then followed by differentiation of the cells (data not included in 
the manuscripts). This suggests that a relatively fast drop of MYCN concentration initiates 
differentiation and growth arrest, rather than an absolute concentration threshold. This 
however is an issue that must be further investigated before any conclusions can be drawn. 
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5.2. Paper III 
5.2.1. Brief description of the study 
MYCN was downregulated using transient shRNA in the MNA cell lines SKNBE(2) and 
Kelly. MiRNA expression profiling was performed on two independent experiments, and 
miRNAs differentially expressed as a result of MYCN silencing were identified. We found 
most members of the three clusters of the miR 17 family to correlate with MYCN expression, 
an observation supported by previous findings. Moreover, we observed a clear correlation 
between MYCN and miR-92b and miR-103. Several non-clustered miRNAs were found to be 
negatively correlated by MYCN.  
The miRNA that was most upregulated following MYCN suppression was miR-21, a miRNA 
that has been shown to act as an oncomir in a range of other tumours. The potential function 
of miR-21 in neuroblastoma was investigated further, but no effect on proliferation or 
differentiation was observed. Hence, we were not able to establish any role for miR-21 
expression in differentiating neuroblastoma cells.  
5.2.2. Discussion 
Apart from the members of the miR 17 family, we observed two miRNAs potentially being 
upregulated by MYCN: miR-92b and miR-103, neither of which have been experimentally 
validated as direct MYCN targets.  
MiR-103 expression is linked to mesenchymal stem cells [reviewed in 287], which have been 
recently argued to be a sub-population of neural crest cells [288]. MiR-103 is expressed in the 
majority of human cells, but is generally more expressed in the brain. It is expected to be 
involved in metabolism. So far, oesophageal carcinoma is the only cancer in which it has a 
prognostic value [reviewed in 289].  
MiR-92b appears to be a miRNA that is primarily expressed in neuronal-specific stem cells, 
the developing brain or brain tumours [290]. Deep sequencing has shown that miR-92b is 
highly expressed in human embryonic stem cells, but diminishes during differentiation [291]. 
In stem cells, miR-92b has been reported to push cells to a proliferative state by 
downregulating p57 [292]. Despite the indications of miR-92b being an oncomir in neural 
neoplasms, very little has been done to elucidate its potential role in various cancers. 
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We also found 11 miRNAs inversely correlated to MYCN expression, with many of these 
being shown to be involved in neuronal differentiation in other cell systems. Theoretically, 
some of these miRNAs could be tumour suppressors inhibited by MYCN, though MYCN is 
predominately a transcriptional activator, and has not yet been shown to directly repress any 
miRNA. Thus, miRNAs being inhibited by MYCN are expected to be regulated in an indirect 
manner. The miRNA most elevated after MYCN silencing was miR-21. This miRNA has been 
shown to be highly expressed in a variety of tumours and acts as an oncomir [293]. In 
addition, increased miR-21 expression has been documented in differentiating SH-SY5Y non-
MNA neuroblastoma cells [294]. We did not find any effects on neither proliferation nor 
differentiation when miR-21 mimics or miR-21 antagomirs were introduced to the SK-N-
BE(2) cell line. Furthermore, miR-21 antagomir did not inhibit differentiation when MYCN 
was downregulated. This indicates that miR-21 does not have a proliferative effect in MNA 
neuroblastoma and that its increase is a consequence of differentiation. Even so, we were not 
able to reveal a functional role for miR-21 during the differentiation of neuroblasotoma cells. 
The lack of phenotypic changes observed by miR-21 mimics and antagomirs are in 
accordance with data recently published by Mestdagh et al. [295]. Here, miRNAs correlating 
with MYCN (i.e. possibly transactivation targets of MYCN) were shown to have strongly 
predicted target enrichment on mRNAs negatively correlated to these miRNAs (i.e. possible 
targets for MYCN-activated miRNAs). This was not the case for miRNAs negatively 
correlated with MYCN and their putative targets. These observations suggest that it is 
primarily MYCN-activated miRNAs that account for the miRNA-mediated regulation of 
mRNAs. 
41 
5.3. Paper IV 
5.3.1. Brief description of the study 
Bell et al. have shown that the transcription of the Wnt antagonist DKK3 is downregulated by 
MYCN. Koppen et al. later revealed that this regulation was in an indirect manner. By 
conducting an in silico analysis we found that both miR-92a and miR-92b, two of the miRNAs 
upregulated by MYCN in Paper III, shared a predicted miRNA target site on the DKK3 3’ 
UTR sequence. Additionally, members of the let-7 family were predicted to bind to another 
target site. We hypothesised that MYCN regulates DKK3 expression through miRNAs.  
By the use of ELISA, we first demonstrated that DKK3 secretion in the culture medium was 
increased when MYCN was downregulated using the inducible Kelly and SK-N-BE(2) RV-
1658 cell lines described in Paper II and the SHEP Tet21N cell line. The DKK3 3’ UTR 
sequence was cloned downstream of the luciferase gene, and repression of the luciferase 
expression was observed when cotransfecting these constructs with mimics of miR-92a, miR-
92b and let-7e. Mutation of the target sites led to a complete rescue of luciferase expression 
for miR-92a and miR-92b, but not for let-7e. The reduction of miR-92a and miR-92b using 
antagomirs led to an increased secretion of DKK3 in the MNA cell lines SK-N-BE(2) and 
Kelly, while transfection of miR-92a and miR-92b mimics into non-amplified cell lines SK-N-
AS and SH-SY-5Y led to downregulation of DKK3 expression. Let-7e mimics only led to a 
moderate reduction of DKK3 levels compared to those obtained by the miR-92a and miR-92b 
mimics. DKK3 measurements were performed by ELISA and qRT-PCR. We also performed 
methylation-specific PCR on genomic DNA from 10 primary neuroblastoma samples (five 
MNA, five non-MNA) and five neuroblastoma cell lines (three MNA, two non-MNA), and 
found no hypermethylation of the DKK3 promoter.  
The immunohistochemistry of 25 primary neuroblastoma tissue samples from various 
biological subsets showed an inverse correlation between the expression of MYCN and DKK3. 
DKK3 was mainly detected in the vasculature of the tumours, illustrated by its co-localisation 
with the vascular endothelial marker CD31. 
42 
5.3.2. Discussion 
DKK3 is a secreted antagonist of the Wnt pathway. To establish whether MYCN 
downregulates DKK3 secretion, we utilised the RV-1658 cell lines described in Paper II as a 
model system. This system was well suited for these experiments since we could suppress 
MYCN for a longer period, thereby allowing the cells to differentiate for five days before 
measuring DKK3 levels. Fresh media were then added to the cells 24 hrs prior to the 
measurement of accumulated DKK3 by enzyme-linked immunosorbent assay (ELISA). To 
the best of our knowledge, this is the first time changes in the secretion of endogenous DKK3 
protein have been measured directly in neuroblastoma. Previous studies have either measured 
mRNA levels or the expression of ectopic Flag-tagged DKK3 [270, 277, 278]. Nonetheless, 
we cannot be certain that the observed upregulation of DKK3 following MYCN silencing is 
solely the effect of changes in miR-92a/b and let-7 alone, or whether additional unknown 
factors are involved. 
We have established that DKK3 expression is regulated by miR-92a, miR-92b and let-7. In 
Paper III, we showed that miR-92a and 92b are downregulated when MYCN expression is 
repressed. Two separate miR-92a genes are found in the human genome, one in the miR-17-92 
cluster and one in the paralogue miR-106a cluster, and both clusters are direct transcriptional 
targets of MYCN [261, 262]. MiR-92b is expressed as a single intergenic miRNA on 
chromosome 1q, and little is known about the promoter of miR-92b. An E-box is located 
upstream of the miR-92b gene, but no ChIP analysis has been performed to investigate 
whether this is a direct binding site for MYCN. The mature sequence of miR-92b is identical 
to that of miR-92a apart from three nucleotides, which does not theoretically impair with seed 
sequence binding. Thus, miR-92a and miR-92b share the same targets. MiR-92b is mainly 
expressed in neuronal-specific stem cells, the developing brain or brain tumours [290]. The 
expression of miR-92b instead of miR-92a in these tissues could be an approach for targeting 
miR-92a/b binding sites, while avoiding expression of the remaining miRNAs of the miR-17-
92 cluster. Since the miR-17-92 cluster is a direct target of MYCN, the distinct expression of 
miR-92b is probably governed by other mechanisms. 
The biological function of DKK3 is debated. DKK3 knock-out mice are viable, fertile and 
show no obvious abnormalities [296]. The lack of a distinct DKK3 knockout phenotype might 
be a result of Soggy replacing DKK3 in important pathways. Although DKK3 does not 
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interact with LRP5/6 [270], DKK3-mediated repression of the canonical Wnt pathway has 
been reported in some cellular settings [272, 273]. Others have reported Wnt activation as a 
result of DKK3 expression [271]. A proposed mechanism for DKK3-mediated activation of 
the Wnt pathway has been described by Nakamura et al. [270], whereas the mechanism of 
DKK3-mediated inhibition of the canonical Wnt pathway remains unknown. Upon discovery 
of the inverse correlation between MYCN and DKK3, Bell et al. proposed that MYCN could 
exert its proliferative effect by allowing high canonical Wnt signalling through 
downregulation of the Wnt inhibitor DKK3 [278]. However, Koppen et al. later documented 
that DKK3 reduces proliferation in neuroblastoma cells, but not through the canonical Wnt 
pathway [277]. Here, it was suggested that DKK3 may exert its effect through the non-
canonical Wnt pathways. It was also debated whether the Wnt pathway was a significant 
contributor to malignancy in MNA neuroblastoma. It has been demonstrated that the 
canonical Wnt pathway is deregulated in high-risk non-MNA neuroblastoma, but not in MNA 
neuroblastoma. In high-risk non-MNA neuroblastoma, this was proposed to cause increased 
proliferation as a result of a higher expression of MYCC and cyclinD [297].  
DKK3 is shown to be necessary for Activin/nodal (members of the transforming growth 
factor beta (TGF-β) superfamily) signalling in Xenopus embryos [298]. Here, DKK3 was 
shown to exert its function by maintaining normal levels of Smad4, a key downstream 
mediator of all TGF-β pathways. TGF-β signalling induces inhibition of proliferation and 
increased differentiation of many neuroblastoma cells, and it has been proposed that the effect 
of retinoic acid is dependent on establishing and maintaining a negative autocrine growth loop 
involving TGF-β1 [299]. It was also proposed that failure to establish such a loop might be a 
reason for the resistance to retinoic acid shown by many neuroblastoma cell lines. These 
results implicate that the loss of DKK3 could theoretically be a reason for a loss of 
responsiveness to TGF-β signalling. Another member of the TGF-β family shown to be of 
relevance in neuroblastoma is Activin A. Schramm et al. revealed that enhanced expression of 
Activin A suppresses proliferation and colony formation in MNA neuroblastoma cells. It also 
inhibits neuroblastoma growth and angiogenesis in vivo, and is highly expressed in 
differentiated, but not undifferentiated neuroblastomas [300, 301]. Activin A also seems to be 
downregulated by MYCN [302]. This potential role of DKK3 in TGF-β signalling is highly 
speculative, and further investigations are needed in order to elucidate whether DKK3 does 
interact with TGF-β signalling in neuroblastoma. 
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We analysed a selection of primary tumours by immunohistochemistry, and found that DKK3 
was expressed in the tumour endothelium. The amount of DKK3 in the endothelium was 
inversely correlated to MYCN amplification. Expression of DKK3 in the tumour endothelium 
rather than the tumour parenchyma has been described in many other types of cancer [303-
308]. Untergasser et al. used murine melanoma cells with ectopical overexpression of DKK3 
to establish xenografts in mice. They observed that DKK3 overexpression resulted in slightly 
larger tumours with a significantly increased microvessel density (MVD) [304]. MVD is a 
measure of angiogenesis which is considered a prognostic indicator that correlates with an 
increased risk of metastasis in various epithelial cancers. These results, and the observation of 
a high expression of DKK3 in the developing heart and blood vessel system in both mice and 
chicken embryos, suggests that DKK3 has a conserved role in vascularisation [309]. The 
observations of DKK3 functioning as an inducer of angiogenesis is contradictory to its 
established role as a tumour suppressor. Compared to low-risk ganglioneuromas, we observed 
lower expression of DKK3 in the vasculature of high-risk MNA neuroblastomas, an 
observation which is supported by others [277].  
In summary it seems as if DKK3 has distinct roles in cancer cells and epithelial cells involved 
in angiogenesis. In pancreatic cells, the pro-angiogenetic effect of DKK3 did not contribute to 
a poor prognosis [303]. Very little is known of the exact function of DKK3 as a tumour 
suppressor in neuroblastoma. It does not seem to influence the canonical Wnt pathway, but 
could be involved in regulation of some of the non-canonical pathways. However, none of the 
Wnt pathways has so far been shown to play a significant role in contributing to the 
proliferation in MNA neuroblastoma. There is a theoretical possibility that DKK3 are 
involved in TGF-β signalling in neuroblastoma, but no research has thus far confirmed this.   
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6. Conclusions 
In this thesis we have focused on the oncogene MYCN that is often amplified in 
neuroblastoma. We have designed and developed a system that allows conditional expression 
of any shRNA from a Tet-inducible RNA polIII H1 promoter (Paper I). In Paper II we used 
this Tet-inducible promoter to express an anti-MYCN shRNA in two MNA neuroblastoma cell 
lines. The shRNA was introduced to the genome of the cells by the use of an MLV based 
retroviral vector system. Efficient suppression of MYCN was observed within 3 days after 
addition of the inducer Dox to the media. 
In Paper III the effect of MYCN suppression on miRNA expression was investigated. We 
found that MYCN downregulation resulted in a decrease of several miRNAs, many of which 
are members of the miR 17 family. In addition we found several miRNAs being upregulated 
as MYCN was suppressed. One of these was miR-21, which was investigated further. We 
could not reveal any function for miR-21 in differentiation or proliferation in MNA 
neuroblastoma.  
Other miRNAs demonstrated to be affected by MYCN expression were miR-92a, miR-92b and 
let-7e.  In Paper IV we showed that these three miRNAs suppresses the expression of DKK3, 
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